BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Head and neck cancer AND SOX2, MGC2413, 6657, ENSG00000181449, MCOPS3, P48431, ANOP3 AND Treatment
105 results:

  • 1. sox2 promotes a cancer stem cell-like phenotype and local spreading in oral squamous cell carcinoma.
    Sacco A; Battaglia AM; Santamaria G; Buffone C; Barone S; Procopio A; Lavecchia AM; Aversa I; Giorgio E; Petriaggi L; Cristofaro MG; Biamonte F; Giudice A
    PLoS One; 2023; 18(12):e0293475. PubMed ID: 38096163
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Super-enhancer driven sox2 promotes tumor formation by chromatin re-organization in nasopharyngeal carcinoma.
    Liu SX; Wang C; Lin RB; Ding WY; Roy G; Wang HB; Yang T; Liu Q; Luo YL; Jin SL; Zeng MS; Zhao B; Zhong Q
    EBioMedicine; 2023 Dec; 98():104870. PubMed ID: 37967508
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Targeted Proteomic Quantitation of NRF2 Signaling and Predictive Biomarkers in HNSCC.
    Wamsley NT; Wilkerson EM; Guan L; LaPak KM; Schrank TP; Holmes BJ; Sprung RW; Gilmore PE; Gerndt SP; Jackson RS; Paniello RC; Pipkorn P; Puram SV; Rich JT; Townsend RR; Zevallos JP; Zolkind P; Le QT; Goldfarb D; Major MB
    Mol Cell Proteomics; 2023 Nov; 22(11):100647. PubMed ID: 37716475
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. METTL3-stabilized super enhancers-lncRNA SUCLG2-AS1 mediates the formation of a long-range chromatin loop between enhancers and promoters of sox2 in metastasis and radiosensitivity of nasopharyngeal carcinoma.
    Hu X; Wu J; Feng Y; Ma H; Zhang E; Zhang C; Sun Q; Wang T; Ge Y; Zong D; Chen W; He X
    Clin Transl Med; 2023 Sep; 13(9):e1361. PubMed ID: 37658588
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Vemurafenib activates the sonic hedgehog pathway and promotes thyroid cancer stem cell self-renewal.
    Lu Y; Zhao Y; Liu P; Xu X
    Endocr Relat Cancer; 2023 Nov; 30(11):. PubMed ID: 37643458
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Methyltransferase-like 3 facilitates the stem cell properties of esophageal cancer by upregulating patched homolog 1 via N6-methyladenosine methylation.
    Liang H; Fang C; Zhang L
    Am J Physiol Cell Physiol; 2023 Sep; 325(3):C770-C779. PubMed ID: 37575058
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. IL-1RA promotes oral squamous cell carcinoma malignancy through mitochondrial metabolism-mediated EGFR/JNK/sox2 pathway.
    Yuan SF; Wang YM; Chan LP; Hung AC; Nguyen HDH; Chen YK; Hu SC; Lo S; Wang YY
    J Transl Med; 2023 Jul; 21(1):473. PubMed ID: 37461111
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. GSK3β-driven sox2 overexpression is a targetable vulnerability in esophageal squamous cell carcinoma.
    Kang L; Liu Y; He J; Wang Y; Xue M; Wu X; Wang Z; Zhang Y; Chu M; Li J; Wei W; Li J; Li E; Liao L; Xiao J; Zhang R; Xu L; Wong J
    Oncogene; 2023 Jul; 42(30):2297-2314. PubMed ID: 37349645
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Reactivated thyroid hormone receptor β attenuates anaplastic thyroid cancer (ATC) stem cell activity.
    Zhu X; Zhao L; Doolittle WKL; Cheng SY
    Endocr Relat Cancer; 2023 Jun; 30(6):. PubMed ID: 36939877
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Osteogenic and Adipogenic Differentiation Potential of Oral cancer Stem Cells May Offer New treatment Modalities.
    Jaksic Karisik M; Lazarevic M; Mitic D; Nikolic N; Milosevic Markovic M; Jelovac D; Milasin J
    Int J Mol Sci; 2023 Feb; 24(5):. PubMed ID: 36902135
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. MicroRNA-101-3p inhibits nasopharyngeal carcinoma cell proliferation and cisplatin resistance through ZIC5 down-regulation by targeting sox2.
    Li T; Zhang G; Li W; Xiao J; Zhou Z; Tan G; Ai J
    Biol Chem; 2023 Sep; 404(10):961-975. PubMed ID: 36752150
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. An anti-alcoholism drug, disulfiram and copper complex improves radio-resistance of tumor-initiating cells in esophageal squamous cell carcinoma.
    ; ; . PubMed ID: 36121574
    [TBL] [Abstract] [Full Text] [Related]  

  • 13.
    ; ; . PubMed ID:
    [No Abstract]    [Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]    [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]    [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]    [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]    [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]    [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]    [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]    [Full Text] [Related]  


    [Next]

    of 6.